Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effects of some androgenic-myotrophic steroids on pubertal ovulation in rats were studied. Treatment began at age 32 days. Steroids were given subcutaneously for 14 consecutive days. Autopsy was on the fifteenth day. The control animals showed an ovulation rate of 98% (137/140 rats). All of the steroids tested suppressed ovulation but differed in their potencies. Testosterone (7 rats ovulating/10 in group), dihydrotestosterone (5/10), nortestosterone (4/10), and norethandrolone (6/10) showed inhibitory effects at a dose of 20 micrograms/day. Nortestosterone seemed most effective, reducing ovulation to 10% at a daily dose of 40 micrograms. Androstenedione, methandrostenolone, oxymetholone, oxandrolone, ethylestrenol, and stanozolol required doses of 100 micrograms or more to depress ovulation. With most of the steroids the ovarian weight depression correlated exactly with ovulation suppression in regard to dose. Half of the compounds decreased uterine weight at lower doses but increased it at higher doses within the dosage range (1-4000 micrograms/day). Dihydrotestosterone, oxymetholone, and ethylestrenol caused uterine weight depression, norethandrolone caused uterine weight stimulation, and oxandrolone had no significant effect on this variable. All of the compounds except testosterone, methandrostenolone, and oxymetholone failed to increase body weight. The ovulation suppression, reduced ovarian weight, and reduced uterine weight observed probably are associated with antigonadotropic activity. For purposes of human contraception it is hoped a separation can be achieved by molecular modification between androgenicity and antiovulatory activity.
 ...
PMID:Anti-ovulatory effects of some androgenic-myotrophic steroids in the pubertal rat. 465 Jun 62

Many studies report the negative correlation between the endogenous testosterone (T) level and majority of risk factors for arteriosclerosis, as well as the presence and the extent of coronary artery disease (CAD) in men. Dihydrotestosterone (DHT) as a non-aromatizable androgen produces more favourable changes in the hormone profile than T. A constant level of androgens, independent on liver function, may be achieved by their transdermal administration. The aim of our study was to determine in a double-blind placebo study whether a 12-week treatment with transdermal DHT can decrease exercise-induced ischaemia in males with CAD. All patients underwent symptom-limited treadmill stress testing at the beginning of the study and after DHT treatment. The selected preliminary results are presented in this paper. Until now the study group has comprised ten men with stable CAD and decreased morning total T concentration. No side effects of treatment were noted during the study. Chronic DHT administration increased significantly: total exercise time, time to the onset of angina and time to 1 mm ST depression. Our results are consistent with the previous publications investigating T effects. The changes of heart rate and systolic blood pressure indicate rather direct coronary-relaxing effect of DHT than peripheral one.
 ...
PMID:[Effect of dihydrotestosterone treatment on exercise induced ischemia in men with stable ischemic heart disease]. 1108 18